The company said net revenue for the fiscal year ended June 30, 2024 rose to $4,685.3 million from $4,223.0 million a year earlier, an increase of 11%, and gross profit rose 13% to $2,655.3 million.

10-KAnnual reportFiled Aug 9, 2024Period of report Jun 30, 2024Summary published (UTC) Oct 24, 2026

Key points

AI summary

The company said net revenue for the fiscal year ended June 30, 2024 rose to $4,685.3 million from $4,223.0 million a year earlier, an increase of 11%, and gross profit rose 13% to $2,655.3 million.
ResMed said annual net revenue from Sleep and Respiratory Care was $4,101.2 million, up 10%, and net revenue from SaaS was $584.1 million, up 17%. It said the SaaS increase was driven mainly by MEDIFOX DAN, which it acquired on November 21, 2022, and that excluding that acquisition, SaaS revenue rose 9%.
The company said annual gross margin rose to 56.7% from 55.8% in the prior year. It attributed the improvement mainly to reduced freight and manufacturing cost improvements, partly offset by combined expenses of $14.3 million associated with field safety notifications for masks with magnets and Astral devices.
The company said net cash provided by operating activities was $1,401.3 million, compared with $693.3 million a year earlier, and that net cash used in financing activities was $1,119.3 million. This included share repurchases of $150.0 million and cash dividends of $1.92 per share, totaling $282.3 million.

Key figures

Fiscal year ended June 30, 2024

Revenue: $4.7B
Operating income: $1.3B
Net income: $1.0B
EPS: $6.92
Gross profit: $2.7B
Operating cash flow: $1.4B

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Annual Net Revenue and Gross Profit

The company said net revenue for the fiscal year ended June 30, 2024 rose to $4,685.3 million from $4,223.0 million a year earlier, an increase of 11%, and gross profit rose 13% to $2,655.3 million.

Source · Based on the MD&A text of the filing

Net Revenue by Segment: Sleep and Respiratory Care and SaaS

ResMed said annual net revenue from Sleep and Respiratory Care was $4,101.2 million, up 10%, and net revenue from SaaS was $584.1 million, up 17%. It said the SaaS increase was driven mainly by MEDIFOX DAN, which it acquired on November 21, 2022, and that excluding that acquisition, SaaS revenue rose 9%.

Source · Based on the MD&A text of the filing

Gross Margin and Field Safety Notification Expenses

The company said annual gross margin rose to 56.7% from 55.8% in the prior year. It attributed the improvement mainly to reduced freight and manufacturing cost improvements, partly offset by combined expenses of $14.3 million associated with field safety notifications for masks with magnets and Astral devices.

Source · Based on the MD&A text of the filing

Operating Cash Flow and Financing Cash Flow

The company said net cash provided by operating activities was $1,401.3 million, compared with $693.3 million a year earlier, and that net cash used in financing activities was $1,119.3 million. This included share repurchases of $150.0 million and cash dividends of $1.92 per share, totaling $282.3 million.

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.